Ionis Pharmaceuticals (IONS) announced that the FDA has granted Breakthrough Therapy designation to zilganersen for the treatment of Alexander disease.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals granted Breakthrough Therapy designation for olezarsen
- Arrowhead price target raised to $48 from $27 at Goldman Sachs
- Ionis Pharmaceuticals Completes $770M Convertible Notes Offering
- Ionis Pharmaceuticals announces CHMP opinion recommending Dawnzera approval
- Arrowhead price target raised to $45 from $29 at Morgan Stanley